Literature DB >> 19355801

Challenges for managing overactive bladder and guidance for patient support.

Vernon F Schabert1, Tamara Bavendam, Erica L Goldberg, Jeffrey N Trocio, Linda Brubaker.   

Abstract

OBJECTIVE: Describe challenges to improving management of overactive bladder (OAB) outcomes and summarize research findings on critical success factors for supporting OAB treatment. STUDY
DESIGN: A multidisciplinary team collected primary and secondary data, including an OAB-specific survey; a literature review; and an expert panel discussion.
METHODS: A US survey of patients who were prescribed antimuscarinics included topics related to OAB, such as reasons for medication discontinuation. The PubMed database was searched for articles published in the past 10 years on OAB treatment and adherence, and additional publications were reviewed related to health behavior change models. An expert panel reviewed findings and provided perspective.
RESULTS: The survey (n = 5392) showed that, among patients discontinuing OAB medications, 45.4% reported unmet treatment expectations as the reason for discontinuation. Literature review findings supported intervention at the beginning of OAB treatment, specific messages to increase treatment adherence, and involving the healthcare stakeholders most trusted by patients. Implications of OAB patient support were drawn from reviews of the Transtheoretical Model, the Health Belief Model, and social learning theory. The expert panel highlighted desirable attributes of OAB patient education delivered in the medical care setting.
CONCLUSION: Challenges to improving OAB symptom burden and outcomes include underdiagnosis, undertreatment, and patient nonadherence with medications. Patient support of medication adherence may be enhanced by simultaneously supporting the use of nonpharmaceutical lifestyle modifications and behavioral interventions. Healthcare providers acknowledge the need for patient education but lack the time and resources to deliver interventions or monitor patients' progress outside the medical office. Patient support may be achieved through external programs that complement patient-physician interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355801

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  16 in total

1.  Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Authors:  Vik Khullar; Jenelle Foote; Yodit Seifu; Mathias Egermark
Journal:  Int Urogynecol J       Date:  2011-10-18       Impact factor: 2.894

Review 2.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

Review 3.  Percutaneous tibial nerve stimulation and sacral neuromodulation: an update.

Authors:  Priyanka Gupta; Michael J Ehlert; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

4.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

5.  Lower urinary tract symptom prevalence and management among patients with multiple sclerosis.

Authors:  Kristin M Khalaf; Karin S Coyne; Denise R Globe; Edward P Armstrong; Daniel C Malone; Jack Burks
Journal:  Int J MS Care       Date:  2015 Jan-Feb

Review 6.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

7.  Bladder wall micromotion measured by non-invasive ultrasound: initial results in women with and without overactive bladder.

Authors:  Anna S Nagle; Zachary E Cullingsworth; Rui Li; Laura R Carucci; Adam P Klausner; John E Speich
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

8.  Adherence to antimuscarinics in children with overactive bladder.

Authors:  Alexandra Fortin; Valérie Morin; Sophie Ramsay; Pascale Gervais; Stéphane Bolduc
Journal:  Paediatr Child Health       Date:  2017-05-17       Impact factor: 2.253

9.  Overactive bladder, differential diagnosis, and clinical utility of fesoterodine.

Authors:  Jean-Jacques Wyndaele
Journal:  Int J Gen Med       Date:  2012-11-12

Review 10.  Social, economic, and health utility considerations in the treatment of overactive bladder.

Authors:  Emilio Sacco; Daniele Tienforti; Alessandro D'Addessi; Francesco Pinto; Marco Racioppi; Angelo Totaro; Daniele D'Agostino; Francesco Marangi; Pierfrancesco Bassi
Journal:  Open Access J Urol       Date:  2010-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.